Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bausch Health Americas, Inc.
This is a Phase 2a proof of concept study evaluating the safety/efficacy of retigabine vs. placebo in patients with post-herpetic neuralgia. After screening, patients will enter a maximum 6 week titration period followed by a 4 week maintenance period and a 3 week taper phase.
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ability to provide informed consent
Male or female subjects
18-85 years of age
PHN for more than 6 months after the healing of herpes zoster skin rash
Has a pain score at screening and randomization that qualifies
You may not be if
Other significant pain that may potentially confound PHN pain assessment
Previous neurolytic or neurosurgical therapy for PHN
Subject has evidence of a progressive central nervous system (CNS) disease (e.g. CNS lupus, tumors, multiple sclerosis, Alzheimer's), lesion, or encephalopathy
Significant psychiatric or neuropsychiatric disorders including but not limited to severe depression, bipolar disorder or schizophrenia spectrum disorder, history of suicide attempt, or recent history of suicidal ideation
Has clinically significant abnormalities on physical examination, vital signs, ECG, or laboratory tests at the screening visit
